A
Aitiologic
Austria · Biotech
A precision-medicine company developing liquid-biopsy tests that interpret cell-free DNA signals for early disease risk assessment.
Product and mechanism
Aitiologic’s Aitios platform analyses genomic, epigenomic and fragmentomic signals from a routine blood draw to infer tissue-specific information. Its lead application is first-trimester risk stratification for preeclampsia using the same sample collected in prenatal testing.
Customers and use
The company is preparing large-scale validation of the lead test after early feasibility results. The platform remains in development; the company’s site describes the technology and its clinical research but does not present it as an approved diagnostic.
- Headquarters
- Vienna, Austria.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed | €6.4M | Ananda Impact Ventures — LeadHeal Capital — LeadDr. Gordon Sanghera CBE FRS — ParticipantLANA Ventures — ParticipantPUSH VC — Participant |